阿托伐他汀钙 结晶型（CAS 344423-98-9）：分子式 C66H68CaF2N4O10、分子量 1155.3。
| CAS号 | 344423-98-9 |
|---|---|
| 分子式 | C66H68CaF2N4O10 |
| 分子量 | 1155.3 |
| 应用领域 | Uses: Use (kg) in Switzerland (2009): >1000、Use (kg、approx.) in Germany (2009): >1000、Use (kg) in USA (2002): 31300、Use (kg) in France (2004): 7924、Consumption (g per capita) in Switzerland (2009): 0.13、Consumption (g per capita、approx.) in Germany (2009): 0.012、Consumption (g per capita) in the USA (2002): 0.11、Consumption (g per capita) in France (2004): 0.13、Excretion rate: 0.46、Calculated removal (%): 97.3、May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI)、stroke、angina、and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia、homozygous familial hypercholesterolemia、primary dysbetalipoproteinemia、and、or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C)、apolipoprotein B (apoB)、and triglyceride concentrations、while increasing high-density lipoprotein cholesterol (HDL-C) levels. |
登记用途：Uses: Use (kg) in Switzerland (2009): >1000、Use (kg、approx.) in Germany (2009): >1000、Use (kg) in USA (2002): 31300、Use (kg) in France (2004): 7924、Consumption (g per capita) in Switzerland (2009): 0.13、Consumption (g per capita、approx.) in Germany (2009): 0.012、Consumption (g per capita) in the USA (2002): 0.11、Consumption (g per capita) in France (2004): 0.13、Excretion rate: 0.46、Calculated removal (%): 97.3、May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI)、stroke、angina、and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia、homozygous familial hypercholesterolemia、primary dysbetalipoproteinemia、and、or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C)、apolipoprotein B (apoB)、and triglyceride concentrations、while increasing high-density lipoprotein cholesterol (HDL-C) levels.。
阿托伐他汀钙 结晶型 是一种化工化合物，登记 CAS 号为 344423-98-9，分子式 C66H68CaF2N4O10（分子量 1155.3）。
登记 CAS 号：344423-98-9
其分子式 C66H68CaF2N4O10 由 66 个碳、68 个氢、1 个钙、2 个氟、4 个氮、10 个氧 组成。
别名/同义词：阿托伐他汀钙 结晶型 · calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3)
阿托伐他汀钙 结晶型 的 CAS 登记号为 344423-98-9。
分子式 C66H68CaF2N4O10，分子量 1155.3。
别名/同义词：阿托伐他汀钙 结晶型、calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate hydrate (1:2:3)。
登记用途：Uses: Use (kg) in Switzerland (2009): >1000、Use (kg、approx.) in Germany (2009): >1000、Use (kg) in USA (2002): 31300、Use (kg) in France (2004): 7924、Consumption (g per capita) in Switzerland (2009): 0.13、Consumption (g per capita、approx.) in Germany (2009): 0.012、Consumption (g per capita) in the USA (2002): 0.11、Consumption (g per capita) in France (2004): 0.13、Excretion rate: 0.46、Calculated removal (%): 97.3、May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI)、stroke、angina、and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia、homozygous familial hypercholesterolemia、primary dysbetalipoproteinemia、and、or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C)、apolipoprotein B (apoB)、and triglyceride concentrations、while increasing high-density lipoprotein cholesterol (HDL-C) levels.。
阿托伐他汀钙 结晶型（CAS 344423-98-9）的独立参考数据，整理自公开化学数据库。
| CAS 号 | 344423-98-9 |
|---|---|
| PubChem CID | 60822 |
| 分子式 | C66H68CaF2N4O10 |
| IUPAC 名称 | calcium bis((3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate) |
| UNII（FDA） | C0GEJ5QCSO |
| Molecular Weight | 1155.3 |
|---|---|
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 22 |
| Exact Mass | 1154.4529416 |
| Monoisotopic Mass | 1154.4529416 |
| Topological Polar Surface Area | 229 |
| Heavy Atom Count | 83 |
ATORVASTATIN CALCIUM; 134523-03-8; Tahor; Atorvastatin calcium anhydrous; CI-981; Liprimar; C0GEJ5QCSO; DTXSID6044303; Atorvastatin calcium (anhydrous); NSC-758617; DTXCID4024303; CHEBI:50686; Atorvastatin calcium salt anhydrous; Dengue Kill; RefChem:916455; Atorvastatin, Calcium salt
| GHS 通报统计 | 2% (3 / 153) |
|---|
| GHS 通报统计 | 2% (3 / 153) |
|---|---|
| 已通报的危害声明 | H315 (37.3%), H319 (38.6%), H335 (37.3%), H361 (37.3%), H362 (36.6%), H373 (36.6%), H402 (19%), H411 (35.9%) |
阿托伐他汀钙 结晶型 · CAS 344423-98-9 · C66H68CaF2N4O10. UNII C0GEJ5QCSO.
数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。